- Record: found
- Abstract: found
- Article: not found
Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.
C Louvet
1 ,
R Labianca ,
P Hammel ,
G Lledo ,
M G Zampino ,
T André ,
A Zaniboni ,
M Ducreux ,
E Aitini ,
J Taïeb ,
R Faroux ,
C Lepere ,
A de Gramont
May 20 2005
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Gemcitabine (Gem) is the standard treatment for advanced pancreatic cancer. Given the promising phase II results obtained with the Gem-oxaliplatin (GemOx) combination, we conducted a phase III study comparing GemOx with Gem alone in advanced pancreatic cancer.